Advertisement
Advertisement
COLL
Collegium Pharmaceutical, Inc. Common Stock
39.59
USDSponsored
-0.40
-0.99%
Mar 04, 15:59 UTC -5
Closed
After-Market
39.60
+0.01
+0.03%
COLL Earnings Reports
Positive Surprise Ratio
COLL beat 19 of 41 last estimates.
46%
Next Report
Date of Next Report
May 06, 2026
Estimate for Q1 26 (Revenue/ EPS)
$192.95M
/$1.66
Implied change from Q4 25 (Revenue/ EPS)
-6.08%
/-18.63%
Implied change from Q1 25 (Revenue/ EPS)
+8.55%
/+11.41%
Collegium Pharmaceutical, Inc. Common Stock earnings per share and revenue
On Feb 26, 2026, COLL reported earnings of 2.04 USD per share (EPS) for Q4 25, missing the estimate of 2.37 USD, resulting in a -14.08% surprise. Revenue reached 205.45 million, compared to an expected 210.49 million, with a -2.39% difference. The market reacted with a -3.34% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 5 analysts forecast an EPS of 1.66 USD, with revenue projected to reach 192.95 million USD, implying an decrease of -18.63% EPS, and decrease of -6.08% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Harrow, Inc. Common Stock
Report Date
Mar 02, 2026 For Q4 25
Estimate
$0.37
Actual
$0.26
Surprise
-30.87%
Definium Therapeutics, Inc. Common Shares
Report Date
Feb 26, 2026 For Q4 25
Estimate
-$0.49
Actual
-$0.50
Surprise
-0.52%
Amylyx Pharmaceuticals, Inc. Common Stock
Report Date
Mar 03, 2026 For Q4 25
Estimate
-$0.36
Actual
-$0.30
Surprise
+18.50%
Xeris Biopharma Holdings, Inc. Common Stock
Report Date
Mar 02, 2026 For Q4 25
Estimate
$0.04
Actual
$0.06
Surprise
+33.63%
Aquestive Therapeutics, Inc. Common Stock
Report Date
Mar 04, 2026 For Q4 25
Estimate
-$0.13
Actual
-$0.26
Surprise
-92.31%
OmniAb, Inc. Common Stock
Report Date
Mar 04, 2026 For Q4 25
Estimate
-$0.09
Actual
-$0.11
Surprise
-21.82%
Cumberland Pharmaceuticals Inc
Report Date
Mar 03, 2026 For Q4 25
Estimate
-Actual
-$0.01
Surprise
-
Amneal Pharmaceuticals, Inc. Class A Common Stock
Report Date
Feb 27, 2026 For Q4 25
Estimate
$0.18
Actual
$0.21
Surprise
+11.52%
Stevanato Group S.p.A.
Report Date
Mar 04, 2026 For Q4 25
Estimate
$0.17
Actual
$0.18
Surprise
+4.55%
Dyne Therapeutics, Inc. Common Stock
Report Date
Mar 02, 2026 For Q4 25
Estimate
-$0.77
Actual
-$0.76
Surprise
+2.28%
FAQ
What were Collegium Pharmaceutical, Inc. Common Stock's earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Collegium Pharmaceutical, Inc. Common Stock reported EPS of $2.04, missing estimates by -14.08%, and revenue of $205.45M, -2.39% below expectations.
How did the market react to Collegium Pharmaceutical, Inc. Common Stock's Q4 2025 earnings?
The stock price moved down -3.34%, changed from $45.75 before the earnings release to $44.22 the day after.
When is Collegium Pharmaceutical, Inc. Common Stock expected to report next?
The next earning report is scheduled for May 06, 2026.
What are the forecasts for Collegium Pharmaceutical, Inc. Common Stock's next earnings report?
Based on 5
analysts, Collegium Pharmaceutical, Inc. Common Stock is expected to report EPS of $1.66 and revenue of $192.95M for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement